24 completed, 4 terminated, 3 withdrawn, 2 active not recruiting. 16 Phase 3, 11 Phase 2, 8 Phase 4, 5 Phase 1, 2 Not applicable.
Follow eicosapentaenoic acid ethyl ester: new trials by email Literature Review of eicosapentaenoic acid ethyl ester trials Research Report on eicosapentaenoic acid ethyl ester
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Icosapent Ethyl for High-Risk Coronary Plaques Assessed by 18F-NaF PET/CT icosapent ethyl (IPE), Standard LDL-C-Lowering Therapy - Coronary Artery Disease, Hyperlipidaemia | Phase 4 | Not yet recruiting | China National Center for Cardiovascular Diseases | 100 | 2026-08-01 | 2026-08-13 |
| A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule, Matching Placebo Subcutaneous Injection - Severe Hypertriglyceridemia | Phase 3 | Not yet recruiting | Zhejiang Doer Biologics Co., Ltd. | 378 | 2026-08-01 | 2026-07-06 |
| Targeting Vascular INflammation in Patients With Community-Acquired Pneumonia Icosapent Ethyl 1000 MG Oral Capsule [Vascepa], Placebo - Inflammation, Community Acquired Pneumonia (CAP) | Phase 3 | Recruiting | Ottawa Heart Institute Research Corporation | 168 | 2026-04-08 | 2026-05-11 |
| CreNeuroS™️CNS Fish Oil Plus Softgels Compared to Vascepa® Capsules and Deplin® Capsules in a Pharmacokinetic, Single Dose Evaluation on Healthy Adult Human Subjects Under Fasting Conditions CreNeuroS CNS Fish Oil Plus Softgel [380 mg of fish oil contains Eicosapentaenoic Acid (EPA) （as EE）342 mg; L-5- Methyltetrahydrofolate 1.875 mg; other Vitamins and Minerals], Vascepa® (Icosapent ethyl) 1000 mg Capsules, Deplin® (L-methylfolate Calcium) 7.5 mg Capsules - Bioavailability | Not applicable | Enrolling by invitation | Sichuan Credit Pharmaceutical Co., Ltd. | 14 | 2025-01-03 | 2025-01-23 |
| Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP) Statin, Aspirin tablet, Nexlizet - Coronary Artery Disease, Atherosclerosis | Phase 4 | Withdrawn | University of Louisville | 2024-03-01 | 2025-03-17 | |
| IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion Icosapent ethyl, Placebo - Aortic Valve Stenosis | Phase 2 | Active not recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 110 | 2023-06-01 | 2025-10-03 |
| Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body Dasatinib, Icosapent Ethyl - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Inflammatory Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 1 | 2022-11-08 | 2025-10-03 |
| Prebiotic Effect of Eicosapentaenoic Acid Treatment for Colorectal Cancer Liver Metastases Icosapent Ethyl Oral Capsule, Placebo - Colon Cancer Liver Metastasis | Completed | University of Leeds | 81 | 2021-09-16 | 2024-12-04 | |
| A PET Study With [11C]PBR-28 and an Experimental Medication, Ethyl Eicosapentaenoic Acid Ethyl Eicosapentaenoic Acid - Bipolar Disorder | Phase 4 | Withdrawn | New York State Psychiatric Institute | 2021-03-19 | 2022-10-14 | |
| PRevention Using EPA Against coloREctal Cancer AMR101 - Colorectal Adenoma, Colorectal Cancer | Phase 1 / Phase 2 | Completed | Massachusetts General Hospital | 81 | 2020-12-09 | 2024-05-03 |
| The Use of Icosapent Ethyl on Vascular Progenitor Cells in Individuals With Elevated Cardiovascular Risk Icosapent Ethyl 1000 MG Oral Capsule [Vascepa] - Cardiovascular Diseases, Cardiovascular Risk Factor | Phase 4 | Completed | Canadian Medical and Surgical Knowledge Translation Research Group | 70 | 2020-09-24 | 2024-04-02 |
| PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial Icosapent ethyl (IPE), Placebo - COVID19 | Phase 3 | Completed | Estudios Clínicos Latino América | 4093 | 2020-08-14 | 2021-09-17 |
| A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults Icosapent ethyl - Covid19, Atherosclerosis | Phase 4 | Terminated | Kaiser Permanente | 39600 | 2020-08-07 | 2023-07-18 |
| An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19 Icosapent ethyl - COVID-19, Inflammatory Response | Phase 2 | Completed | Canadian Medical and Surgical Knowledge Translation Research Group | 100 | 2020-06-04 | 2021-12-22 |
| Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia Omega 3 pentaenoic acid, icosapent ethyl - Hypertriglyceridemia | Phase 2 | Completed | Matinas BioPharma Nanotechnologies, Inc. | 100 | 2020-06-03 | 2022-03-04 |
| OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer AMR101 (VASCEPA, icosapent ethyl) - Colon Cancer | Phase 2 | Withdrawn | Massachusetts General Hospital | 2019-11-30 | 2021-11-17 | |
| The Effect of E-EPA on Circulating LDL and Plasma Lipid Metabolism Ethyl-Eicosapentaenoic Acid (E-EPA) - Atherosclerosis, Low-density Lipoproteins Aggregation Susceptibility | Not applicable | Completed | Wihuri Research Institute | 68 | 2019-11-12 | 2025-09-22 |
| Efficacy of MND-2119 in Participants With Hypertriglyceridemia Icosapent (MND-2119), Icosapent (EPADEL CAPSULES 300) - Hypertriglyceridemia | Phase 3 | Completed | Mochida Pharmaceutical Company, Ltd. | 580 | 2018-10-27 | 2019-08-01 |
| EPA for Metastasis Trial 2 Icosapent Ethyl, Placebo - Liver Metastasis, Colon Cancer | Phase 3 | Active not recruiting | Mark A Hull, PhD FRCP | 418 | 2018-05-02 | 2025-04-18 |
| Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid icosapent ethyl (IPE), gel cap placebo - Alzheimer's Disease | Phase 2 / Phase 3 | Completed | VA Office of Research and Development | 131 | 2017-06-08 | 2024-11-26 |
Showing 20 of 38. Sign in to see all of them.
Hypertriglyceridemia (15) · Dyslipidemias (5) · Cardiovascular Diseases (4) · Coronary Artery Disease (4) · Atherosclerosis (3) · COVID-19 (3) · Colonic Neoplasms (3) · Diabetes Mellitus, Type 2 (3) · Bipolar Disorder (2) · Colorectal Neoplasms (2) · Vascular Diseases (2) · Acute Coronary Syndrome (1) · Alzheimer Disease (1) · Angina Pectoris (1) · Aortic Valve Stenosis (1)
Amarin Pharma Inc. (3) · Canadian Medical and Surgical Knowledge Translation Research Group (2) · Massachusetts General Hospital (2) · Takeda (2) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Amarin Neuroscience Ltd (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · China National Center for Cardiovascular Diseases (1) · Estudios Clínicos Latino América (1) · Kaiser Permanente (1) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (1) · M.D. Anderson Cancer Center (1) · Mark A Hull, PhD FRCP (1) · Matinas BioPharma Nanotechnologies, Inc. (1)
United States (20) · Canada (5) · India (3) · Netherlands (3) · China (2) · Finland (2) · Japan (2) · Russia (2) · South Africa (2) · Ukraine (2) · United Kingdom (2) · Argentina (1) · Australia (1) · Denmark (1) · Germany (1)
Associate Professor, Clinical Cell Biology and Medicine (2) · Mark Hull (2) · Subodh Verma, MD, PhD (2) · Andrew T. Chan, MD, MPH (1) · Blair Leavitt, MD (1) · Christopher Ross, MD, PhD (1) · Cynthia M. Carlsson, MD MS (1) · David A Hess, PhD (1) · David Mischoulon, MD, PhD (1) · Deepak L Bhatt, MD, MPH (1) · Deepak L. Bhatt, MD, MPH (1) · Dinesh Kalra, MD (1) · Ira Shoulson, MD (1) · Jianping Li (1)
PMID 23325450, PMID 25893544, PMID 27206952, PMID 27418543, PMID 27596132, PMID 27939227, PMID 19064745, PMID 19709502, PMID 21683321, PMID 22819432, PMID 23032083, PMID 23312052, PMID 23835245, PMID 23992935, PMID 26073397, PMID 29583081, PMID 30101328, PMID 30415628, PMID 30788718, PMID 30834441, PMID 30898607, PMID 31277790, PMID 31306043, PMID 31439224, PMID 31707829, PMID 33010162, PMID 33148016, PMID 34462732, PMID 34620410, PMID 34706555, PMID 34710343, PMID 34817851, PMID 35027114, PMID 35232215, PMID 35261279, PMID 35377160, PMID 35483753, PMID 35762321, PMID 36802845, PMID 38030258, PMID 38035037, PMID 38156550, PMID 38552629, PMID 39968782, PMID 40982548, PMID 41059572, PMID 41781043, PMID 42349681
R01CA243454 (1), UM1CA186688 (1)